Preferred Label : 2019-nCoV Vaccine mRNA-1273;

MeSH definition : mRNA vaccine against SARS-CoV-2 developed by Moderna.; mRNA vaccine against SARS-CoV-2, developed by Moderna.;

MeSH synonym : 2019 nCoV Vaccine mRNA 1273; mRNA-1273, 2019-nCoV Vaccine; Moderna COVID-19 Vaccine; COVID-19 Vaccine, Moderna; Moderna COVID 19 Vaccine; Vaccine, Moderna COVID-19; Moderna COVID-19 Vaccine RNA; Moderna COVID 19 Vaccine RNA; COVID-19 Vaccine Moderna; COVID 19 Vaccine Moderna; Moderna, COVID-19 Vaccine; mRNA-1273; mRNA 1273;

CISMeF synonym : Elasomeran;

MeSH hyponym : mRNA 1273.211; M 1273; M1273; CX 024414; CX024414; TAK 919; TAK919; Moderna COVID 19 Vaccine, Bivalent;

Related MeSH term : TAK 919; TAK919; M-1273; M 1273; M1273;

UNII : EPK39PL4R4;

Details


Main resources

You can consult :

mRNA vaccine against SARS-CoV-2 developed by Moderna.
mRNA vaccine against SARS-CoV-2, developed by Moderna.

PUBLIÉ LE 18/02/2022
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-28-01-2022-au-10-02-2022
2022
false
false
false
France
French
mRNA Vaccine
mRNA Vaccines
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
mRNA vaccine
Administration of vaccine product containing only severe acute respiratory syndrome coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines

---
PUBLIÉ LE 04/03/2022
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-11-02-2022-au-24-02-2022
2022
false
false
false
France
French
mRNA Vaccine
mRNA Vaccines
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
mRNA vaccine
Administration of vaccine product containing only severe acute respiratory syndrome coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines

---
PUBLIÉ LE 18/03/2022
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-25-02-2022-au-10-03-2022
2022
false
false
false
France
French
mRNA Vaccines
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine
brachial plexus neuritis
anemia, hemolytic, autoimmune
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
Administration of vaccine product containing only severe acute respiratory syndrome coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines

---
PUBLIÉ LE 01/04/2022
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-11-03-2022-au-24-03-2022
2022
false
false
false
France
French
mRNA Vaccines
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
Administration of vaccine product containing only severe acute respiratory syndrome coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines

---
PUBLIÉ LE 15/04/2022
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-25-03-2022-au-07-04-2022
2022
false
false
false
France
French
mRNA Vaccines
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine
vasculitis
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
Administration of vaccine product containing only severe acute respiratory syndrome coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines

---
PUBLIÉ LE 27/12/2022
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-25-11-2022-au-22-12-2022
2022
false
false
false
France
French
mRNA Vaccine
mRNA Vaccines
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine
NVX-CoV2373 adjuvated lipid nanoparticle
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
mRNA vaccine
Administration of vaccine product containing only severe acute respiratory syndrome coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines

---
PUBLIÉ LE 01/08/2022
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-le-covid-19-periode-du-17-06-2022-au-21-07-2022
2022
false
false
false
France
French
mRNA Vaccines
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine
pericarditis
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
Administration of vaccine product containing only severe acute respiratory syndrome coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines

---
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-22-07-2022-au-08-09-2022
2022
false
false
false
France
French
mRNA Vaccines
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
Administration of vaccine product containing only severe acute respiratory syndrome coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines

---
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-le-covid-19-periode-du-2-09-2022-au-29-09-2022
2022
false
false
false
France
French
mRNA Vaccines
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
Administration of vaccine product containing only severe acute respiratory syndrome coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines

---
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-le-covid-19-periode-du-30-09-2022-au-20-10-2022
2022
false
false
false
France
French
mRNA Vaccines
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine
menorrhagia
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
Administration of vaccine product containing only severe acute respiratory syndrome coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines

---
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-21-10-2022-au-24-11-2022
2022
false
false
false
France
French
mRNA Vaccines
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
Administration of vaccine product containing only severe acute respiratory syndrome coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines

---
PUBLIÉ LE 31/05/2022
https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-06-05-2022-au-23-05-2022
2022
false
false
false
France
French
mRNA Vaccines
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine
summary of product characteristics
package leaflet
drug information
pharmacovigilance
adverse drug reaction reporting systems
france
vaccination
Drug-Related side effects and adverse reactions
drug monitoring
Administration of vaccine product containing only severe acute respiratory syndrome coronavirus 2 antigen (procedure)
Covid-19 vaccines
COVID-19
COVID-19 Vaccines

---
Nous contacter.
04/06/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.